Study of Vitamin D in Untreated Metastatic Colorectal Cancer



Status:Active, not recruiting
Conditions:Colorectal Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/14/2019
Start Date:March 2012
End Date:June 2020

Use our guide to learn which trials are right for you!

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer

The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor
in the cancer cells, it may stop cancer cells from growing abnormally and may cause cell
death. Vitamin D has been used in other research studies and information from those other
research studies suggests that Vitamin D may help in the treatment of colorectal cancer.

In this research study, the investigators are comparing standard and higher dose Vitamin D
treatment when given in combination with standard treatment for metastatic colorectal cancer.
Standard treatment includes the chemotherapy combination of 5-FU, Leucovorin and Oxaliplatin
(FOLFOX) with bevacizumab.

Participants will be randomized into one of the study groups-Arm A: Vitamin D (standard dose
of 400 IU/day), FOLFOX and Bevacizumab or Arm B: Vitamin D (higher dose of 8000 IU/day for 2
weeks followed by 4000 IU/day), FOLFOX and Bevacizumab.

Study Treatment (A cycle of treatment is 14 days):

Vitamin D

Cycle 1: You will take two capsules of Vitamin D orally, once a day (at the same time), every
day. Participants randomized to Arm A will be taking one capsule with 400 IU of Vitamin D and
one capsule with placebo (pills with no medicine) so that neither you nor your doctor will
know what group you have been assigned to. Participants randomized to Arm B will be taking
two capsules of 4000 IU each.

Subsequent Cycles: You will take one capsule orally, once a day (at the same time), every
day. Participants randomized to Arm A will be taking one capsule with 400 IU of Vitamin D.
Participants randomized to Arm B will be taking one capsule with 4000 IU of Vitamin D.

FOLFOX and bevacizumab

FOLFOX and bevacizumab will be given intravenously (IV, through a vein in your arm) on Day 1
of every cycle for all participants in both Arms A and B. The infusions will take several
hours, in addition to your doctor's visit, so you should plan on being in clinic most of the
day. Note that the 5-FU is given bolus on day 1 (given as one dose), and is then given as a
continuous IV infusion over 2 days. You will need to have a port-a-cath placed. A port-a-cath
is a medical device that is placed under the skin. The continuous infusion is delivered by a
pump that is inserted into the port-a-cath. The pump will be carried in a pouch that you can
hook around your waist. Arrangements will be made for you to have the pump disconnected after
2 days. You may need to return to clinic to have it disconnected.

While on study, the following tests and procedures will be performed:

Cycle 1, Day 1

- Questions about your health, current medications and any allergies.

- Physical exam, including vital signs

- Performance status

- Routine blood tests to evaluate your health

- Urine test

Subsequent Cycles, Day 1

- Questions about your health, current medications, allergies and any side effects you may
be having.

- Physical exam, including vital signs

- Performance status

- Routine blood tests to evaluate your health

- Urine test

- Review of your study drug diary (please bring with you every visit).

Every 4 cycles (approximately every 8 weeks): An assessment of your tumor by CT scan or MRI.

Additional blood samples for research: Samples will be drawn (a little more than 1 teaspoon
of blood) after Cycle 4, Cycle 8 and then every 8 Cycles thereafter.

You will continue to receive treatment as long as your disease does not get worse and you are
tolerating the treatment.

End of treatment

- Questions about your health, current medications and any allergies.

- Physical exam, including vital signs

- Performance status

- Blood tests (routine blood tests to evaluate your health and a blood sample for
research)

- Urine test

- An assessment of your tumor by CT scan or MRI

After the final dose of the study drug:

You will be followed for safety reasons for 30 days after the last dose of study drug. If you
are experiencing side effects, you may continue to be followed until the side effects resolve
or until you start another treatment.

If you discontinue study treatment for reasons other than disease progression (for example,
side effects), you will be asked to continue to get tumor assessments every 8 - 16 weeks
until your disease worsens as demonstrated by a tumor assessment or until you start another
therapy to treat your cancer. These assessments may coincide with your routine follow-up, in
which case they would not need to be repeated.

We would like to keep track of your medical condition for the rest of your life. We would
like to do this by reviewing your medical records and/or by calling you on the telephone
every 3 months to see how you are doing. Keeping in touch with you and checking on your
condition helps us look at the long-term effects of the research study.

Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the colon or rectum that is metastatic or
locally advanced (unresectable)

- Measurable disease

- KRAS wild-type and KRAS mutant patients are eligible

- No prior systemic treatment for advanced or metastatic colorectal cancer is allowed

- No prior radiotherapy to more than 25% of bone marrow

- No surgery or major biopsy within 4 weeks of randomization

- Paraffin-embedded and/or snap-frozen tumor tissue samples must be available

Exclusion Criteria:

- Not pregnant or breastfeeding

- No prior chemotherapy, systemic therapy or investigational agent

- No concurrent use of other anti-cancer therapy

- No known brain metastases

- No history of other malignancies except adequately treated non-melanoma skin cancer,
curatively treated in situ cancer of the cervix, curatively treated lobular or ductal
carcinoma in situ of the breast or other cancer curatively treated with no evidence of
disease for more than 3 years prior to randomization

- No regular use of vitamin D supplements greater than 2000 IU per day in the past year

- No history of allergic reactions attributed to compounds of similar chemical or
biologic composition to 5-FU, capecitabine, oxaliplatin, leucovorin, bevacizumab
and/or vitamin D3

- No significant history of bleeding events, pre-existing bleeding diathesis,
coagulopathy or gastrointestinal perforation

- No arterial thrombotic events within 6 months of randomization

- No serious non-healing wound, ulcer or bone fracture

- No history of uncontrolled hypertension

- No clinically significant peripheral neuropathy

- No predisposing colonic or small bowel disorders in which the symptoms are
uncontrolled

- No uncontrolled seizure disorder or active neurological disease

- No pre-existing hypercalcemia

- No known active hyperparathyroid disease

- No regular use of thiazide diuretics

- No malabsorption, uncontrolled vomiting or diarrhea

- No known co-morbid disease that would increase the risk of toxicity

- No use of chronic oral corticosteroid therapy or any other therapy that can cause
vitamin D depletion

- No clinically significant cardiovascular disease

- No uncontrolled intercurrent illness

- No history of any medical or psychiatric condition or addictive disorder or laboratory
abnormality that may increase the risks associated with study participation
We found this trial at
18
sites
Laconia, New Hampshire 03246
Principal Investigator: Douglas J. Weckstein, MD
Phone: 603-224-2556
?
mi
from
Laconia, NH
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Principal Investigator: David Ryan, MD
Phone: 617-724-4000
?
mi
from
Boston, MA
Click here to add this to my saved trials
330 Brookline Ave
Boston, Massachusetts 02215
617-667-7000
Principal Investigator: Rebecca Miksad, MD
Phone: 617-667-7000
Beth Israel Deaconess Medical Center Beth Israel Deaconess Medical Center (BIDMC) is one of the...
?
mi
from
Boston, MA
Click here to add this to my saved trials
675 N Saint Clair St # 21-100
Chicago, Illinois 60611
(312) 695-1156
Principal Investigator: Halla S. Nimeiri, MD
Phone: 312-695-1376
Robert H. Lurie Comprehensive Cancer Center at Northwestern University The cancer center was first established...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Emily Chan, MD
Phone: 800-811-8480
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Boise, Idaho 83712
Principal Investigator: Dan S Zuckerman, MD
Phone: 208-381-2711
?
mi
from
Boise, ID
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Kimmie Ng, MD, MPH
Phone: 617-632-5960
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Concord, New Hampshire 03301
Principal Investigator: Douglas J. Weckstein, MD
Phone: 603-224-2556
?
mi
from
Concord, NH
Click here to add this to my saved trials
Fruitland, Idaho 83619
Principal Investigator: Dan S Zuckerman, MD
Phone: 208-381-2711
?
mi
from
Fruitland, ID
Click here to add this to my saved trials
Hooksett, New Hampshire 03106
Principal Investigator: Douglas J. Weckstein, MD
Phone: 603-224-2556
?
mi
from
Hooksett, NH
Click here to add this to my saved trials
Londonderry, New Hampshire
Phone: 603-552-9170
?
mi
from
Londonderry, NH
Click here to add this to my saved trials
295 Varnum Ave
Lowell, Massachusetts 01854
(978) 937-6000
Principal Investigator: Blair Ardman, MD
Phone: 978-937-6258
Lowell General Hospital Welcome to Lowell General Hospital! Our goal is to provide you with...
?
mi
from
Lowell, MA
Click here to add this to my saved trials
Meridian, Idaho 83642
Principal Investigator: Dan S Zuckerman, MD
Phone: 208-381-2711
?
mi
from
Meridian, ID
Click here to add this to my saved trials
Milford, Massachusetts 01757
Principal Investigator: Michael Constantine, MD
Phone: 508-488-3700
?
mi
from
Milford, MA
Click here to add this to my saved trials
Nampa, Idaho 83686
Principal Investigator: Dan S Zuckerman, MD
Phone: 208-381-2711
?
mi
from
Nampa, ID
Click here to add this to my saved trials
2014 Washington St
Newton, Massachusetts 02462
(617) 243-6000
Principal Investigator: Caroline C. Block, MD
Phone: 617-658-6000
Newton-Wellesley Hospital A comprehensive medical center located right in Newton on Washington Street, Newton-Wellesley Hospital...
?
mi
from
Newton, MA
Click here to add this to my saved trials
South Weymouth, Massachusetts
Principal Investigator: Rolf Freter, MD
Phone: 781-624-4800
?
mi
from
South Weymouth, MA
Click here to add this to my saved trials
Twin Falls, Idaho 83301
Principal Investigator: Dan S Zuckerman, MD
Phone: 208-381-2711
?
mi
from
Twin Falls, ID
Click here to add this to my saved trials